Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

Published:2022-01-01 Issue:1 Volume:79 Page:13
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Salloway Stephen¹,Chalkias Spyros²,Barkhof Frederik³⁴,Burkett Patrick²,Barakos Jerome⁵⁶,Purcell Derk⁵⁶,Suhy Joyce⁶,Forrestal Fiona²,Tian Ying²,Umans Kimberly²,Wang Guanfang⁷,Singhal Priya²,Budd Haeberlein Samantha²,Smirnakis Karen²

Affiliation:

1. Warren Alpert Medical School, Brown University, Providence, Rhode Island

2. Biogen, Cambridge, Massachusetts

3. Institutes of Healthcare Engineering and Neurology, University College London, London, United Kingdom

4. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands

5. California Pacific Medical Center, San Francisco

6. Bioclinica, Newark, California

7. Cytel Inc, Waltham, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2786606/jamaneurology_salloway_2021_oi_210073_1641404428.53594.pdf

Reference25 articles.

1. A single ascending dose study of bapineuzumab in patients with Alzheimer disease.;Black;Alzheimer Dis Assoc Disord,2010

2. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer’s disease.;Carlson;Alzheimers Dement (Amst),2016

3. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.;Salloway;Neurology,2009

4. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease.;Ferrero;Alzheimers Dement (N Y),2016

5. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease.;Ostrowitzki;Alzheimers Res Ther,2017

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AAV-aMTD-Parkin, a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson's and Alzheimer’s diseases;Pharmacological Research;2024-10

2. Emerging paradigms in Alzheimer's therapy;European Journal of Pharmacology;2024-10

3. Heed the Warning Signs to Avoid Serious ARIA;Neurology;2024-09-10

4. Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities;Neurology;2024-09-10

5. Updates in Alzheimer's disease: from basic research to diagnosis and therapies;Translational Neurodegeneration;2024-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3